<DOC>
	<DOCNO>NCT02587000</DOCNO>
	<brief_summary>Evaluation efficiency selective progesterone receptor modulators ( SPRM ) ( Ulipristal acetate ) bleed control pain patient adenomyosis wish keep fertility .</brief_summary>
	<brief_title>Adenomyosis Ulipristal Acetate</brief_title>
	<detailed_description>After inclusion accord criterion , 2 arm : placebo Ulipristal acetate ( UA ) 10mg randomisation , 1 patient placebo 3 patient UA . 48 patient include trial . The end point bleeding evaluate Pictorial Blood-loss Assessment Chart ( PBAC ) score , amenorrhea rate pain evaluate visual analogic scale .</detailed_description>
	<mesh_term>Adenomyosis</mesh_term>
	<criteria>Not postmenopausal woman age 30 50 , Accepting give consent inform writing , Suffering symptomatic pelvic endometriosis ( menorrhagia isolate associated pain ) Diagnosis information , confirm adenomyosis ( T2weighted ) MRI and/or transvaginal ultrasonography , 6 month precede inclusionhaving score bleeding ( PBAC ) &gt; 100 J1 J8 menstruation visit inclusion , With index body mass ( IMC ) ≥18 &lt; 40 , Using reliable method nonhormonal contraception ( nonhormonal intrauterine device ( IUDs ) , sexual abstinence , diaphragm , condom vasectomy partner , undergone surgical sterilization ) , Willing able complete autoquestionnaires french Had difficulty understand communicate investigator representative Affiliation social security assign . Patient hormonal oral contraceptive hormonal intrauterine Device ( IUD ) contraceptive Patient history surgery ( caesarean cervical conization ) uterus , ablation endometrial uterine artery embolization , With endometriosis endometrial pathology , Suffering myoma type 0 , 1 , 2 3 , Requiring transfusion ≤6g/dL hemoglobin Existence systemic coagulation , History thromboembolism Progestagen take severe disorder month precede tour selection , corticosteroid aspirin previous week , Existence Pathology renal , respiratory cardiac severe progressive , Having disturb liver function ( defined aspartate aminotransferase ( ASAT ) , Alanine Amino Transferase ( ALAT ) , γGlutamylTranspeptidase , alkaline phosphatase total bilirubin 2 time upper limit normal ) , Existence suspicion malignancy , Considering pregnancy come year , Pregnant patient nurse Any clinical condition investigator considers incompatible conduct study term acceptable security , Participation course another clinical study Patient whose accession test procedure may insufficient long term followup seem difficult achieve Person authorship curator safeguard justice History hypersensitivity ulipristal excipients ESMYA ® 5 mg tablet .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adenomyosis</keyword>
	<keyword>ulipristal acetate</keyword>
	<keyword>sonography</keyword>
	<keyword>Magnetic resonance image [ MRI ]</keyword>
	<keyword>Pictorial Blood-loss Assessment Chart [ PBAC ]</keyword>
</DOC>